
    
      The patients of gastric cancer have been divided into two parts in random.The test group
      receive perioperative chemotherapy (XELOX) six cycles and the control group administrate the
      same program after operation. The two groups have the same staging and eligibility
      criteria.The 3 year disease-free survival (DFS) rate and 5 year overall survival (OS) rate
      maybe the last evaluation standard.
    
  